ThermoGenesis Holdings, Inc. (THMO)

Market Cap	2.22M
Revenue (ttm)	9.61M
Net Income (ttm)	-14.75M
Shares Out	15.85M
EPS (ttm)	-4.75
PE Ratio	n/a
Forward PE	1.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,005
Open	0.130
Previous Close	0.150
Day's Range	0.130 - 0.150
52-Week Range	0.130 - 1.430
Beta	2.29
Analysts	Strong Buy
Price Target	5.00 (+3,468.88%)
Earnings Date	Aug 8, 2024

About THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automat...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1986
• Employees: 25
• Stock Exchange: OTCMKTS
• Ticker Symbol: THMO

Financial Performance

In 2023, THMO's revenue was $9.45 million, a decrease of -9.90% compared to the previous year's $10.48 million. Losses were -$17.98 million, 59.5% more than in 2022.

Analyst Forecast

According to one analyst, the rating for THMO stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(3,468.88% upside)

Analyst Consensus: Strong Buy